MedTrace Logo

Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

NCT04412304 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 166

Last updated 2020-06-22

No results posted yet for this study

Summary

The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.

Conditions

Interventions

DRUG

Dose of Tinzaparin or Dalteparin

The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.

Sponsors & Collaborators

Principal Investigators

  • Maria Cronhjort, PhD · Karolinska Institutet, Department of Clinical Science and Education

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-06
Primary Completion
2020-04-30
Completion
2020-05-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04412304 on ClinicalTrials.gov